Wise Pioneers Lead the Way: Empowering the Digital Future of China's Medical Device Industry — PureGlobal Guangzhou HQ Relocation and Product Overview

On August 30, 2022, an auspicious day, PureDx Guangzhou Headquarters held a grand and solemn housewarming ceremony at its new office located on the 33rd floor of Building A, Guanzhou Life Science Innovation Center, Guangzhou International Bio Island. Ms. Meng Zhu, CEO, attended the event and delivered a speech. On that day, more than seventy friends and partners from various industries traveled across China to Guangzhou to witness PureDx’s relocation celebration, offering their best wishes for the company to seize the momentum and reach new heights.

Ms. Meng Zhu, CEO, led the attendees in a retrospective of the company’s growth over the past two years: “PureDx was founded on June 5, 2020, a date I will cherish for the rest of my life. After returning to China in August 2020, I initially worked from a temporary desk at our partner’s office. We then leased Room 2709 at the Mosaic International Business Center, and shortly thereafter added Room 2802. In June 2021, PureDx established its Suzhou branch. As our team continued to expand, we relocated the entire staff to the 31st floor—the highest floor—of the Mosaic building in the second half of last year. During this period, we also officially launched operations in our Wuhan and Shenzhen offices. The design and renovation of our Shanghai branch office have been completed, with formal operations commencing this April. Thus, PureDx’s domestic commercial footprint has become increasingly clear.”The relocation from the Mosaic building to Guangzhou International Bio Island was both a fortuitous opportunity and a natural progression. Benefiting from talent-support policies and introduced to the island by leaders of the Huangpu District Science and Technology Bureau, PureDx secured the 33rd-floor exhibition space after several rounds of negotiations.

From a global perspective, Prey has established branches in the United States, Canada, Australia, India, Poland, Germany, and other countries while maintaining its base in China. Our overseas clinical bases are primarily located in the United States and Europe, where we possess exclusive clinical resources that are scarce within the industry. These resources enable us to provide product analytical performance evaluations and clinical trials for domestic enterprises. Such robust overseas clinical capabilities can meet the diverse needs of Chinese companies expanding globally with regard to clinical trials.

As an industry-leading global SaaS+Data life sciences service provider, Purui Chunzheng is dedicated to enabling end-to-end digitalization for the global market expansion of medical devices. It provides comprehensive consulting services for global regulatory compliance and market access for medical devices, in vitro diagnostics (IVD), and AI-based medical software products. Its full-suite services cover regulatory consulting, local authorized representation, product certification and registration, overseas clinical trials, technical documentation and quality management system guidance, and product testing.

In addition to providing clients with multi-country registration and overseas clinical services, Purui has independently developed the Global Regulatory Intelligence Platform (GRIP), empowered by its vast data accumulation and innovative next-generation information technologies such as big data and artificial intelligence. Integrating the most up-to-date and comprehensive global market access regulations, clinical trial data, local distributor information, and medical device registration data, GRIP features seven modules—including global compliance, product analysis, project management, and intelligent documentation—to provide comprehensive and robust support for enterprises exporting their medical device products.

It is also worth mentioning that at the sub-forum of the Global Expansion Conference co-hosted by Purui and VCBeat this month, Purui will make its grand debut of the “China Medical Device Enterprise Global Expansion Index.” This index ranks the global expansion performance of all medical device manufacturers listed on China’s A-share market, leveraging the extensive database of Purui’s GRIP platform. The initiative aims to significantly enhance our brand’s credibility and influence in the field of medical device global expansion services.

This year, Purui has continued to enhance its professional standing and influence within the industry. At the Top 100 Conference hosted by VCBeat in June, we received the “Future Healthcare 100 · Weilan Award · 2022 Emerging Entrepreneur” award. Subsequently, we went on to win multiple honors, including the “2022 Gusu Leading Talent Plan for Innovation and Entrepreneurship” award, the “Second Prize in the National Startup Competition of the Digital Healthcare Track at the 2022 Digital China Innovation Contest,” and recognition as one of “Fortune China’s 2022 Most Socially Impactful Startups.”

The Future Is Here.

As an industry pioneer, PureCert is never daunted by any new changes. We will continue to operate as a global SaaS+Data life sciences service provider, strengthening collaboration with our partners to empower Chinese medical device enterprises to brave the winds and waves and stride confidently into a more challenging future!

PureSino is a global SaaS+Data life sciences service provider, with its global service network spanning multiple countries and regions, including China, the United States, the United Kingdom, Germany, the Netherlands, Poland, Malta, and Hong Kong.

Leveraging a world-class team of experts with extensive regulatory certification and clinical experience, PureCert provides end-to-end consulting services for global market compliance and access, as well as one-stop solutions such as overseas clinical trials, for medical devices, in vitro diagnostics (IVD), AI-based medical software, and other products. With market access consultation covering 100+ countries, 1,000+ successful overseas registration/certification cases, big data on 600,000+ global distributors, 1 million+ global clinical trial records, and a database of 3 million+ global medical device registrations, we empower your products to seamlessly achieve compliance and successfully enter the global market—from market strategy data to regulatory consulting!